April 02, 2026 03:46 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead
Johnson And Johnson Vaccine

Johnson & Johnson suspends COVID-19 vaccine trials in Brazil

| @indiablooms | Oct 14, 2020, at 02:54 pm

Brasilia/Xinhua: The Janssen-Cilag company, the pharmaceutical division of US multinational Johnson & Johnson, temporarily suspended clinical trials in Brazil of a vaccine against the novel coronavirus (COVID-19), the national health regulatory body Brazilian Health Surveillance Agency (Anvisa) said on Wednesday.

Janssen-Cilag notified Anvisa that testing to determine the safety and efficacy of its vaccine VAC31518COV3001 "was temporarily suspended due to a serious adverse occurrence in a volunteer abroad."

The company did not provide more details about the case, as the volunteer's health status is kept confidential.

According to Anvisa, the trials will not resume until there is an investigation into the cause of the problem by the Independent Safety Committee, as part of good clinical practice procedures.

"In Brazil, the inclusion of the first volunteer in the study occurred on Oct. 9 and new inclusions can only occur when there is authorization from Anvisa, which will proceed with the analysis of the research data and decide on the continuity or permanent suspension based on the safety and risk/benefit assessment," the agency said.

Janssen-Cilag received authorization from Anvisa in August to carry out the trials in Brazil.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.